Join to View Full Profile
5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-645-4673
Fax+1 214-648-1955
Dr. Bhalla is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2018 - 2021- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2015 - 2018
University of Florida College of MedicineClass of 2015
Certifications & Licensure
TX State Medical License 2021 - 2026
NY State Medical License 2017 - 2021
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC Start of enrollment: 2021 Aug 04
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Association of PD-L1 expression with systemic immune parameters in non-small cell lung cancer.Mary E Gwin, Mitchell S von Itzstein, Jialiang Liu, Farjana J Fattah, Hong Mu-Mosley
Translational Lung Cancer Research. 2025-11-30 - Radiologists' Perceptions of the 21st Century Cures Act.Jessica H Porembka, Emily L Paton, Yin Xi, Ruth C Carlos, Sheena Bhalla
Journal of the American College of Radiology. 2025-10-02 - 1 citationsInnate and adaptive immune features associated with immune-related adverse events.Shaheen Khan, Venkat S Malladi, Mitchell S von Itzstein, Hong Mu-Mosley, Farjana J Fattah
Journal for Immunotherapy of Cancer. 2025-09-10
Press Mentions
AI Tool May Predict Lung Cancer with 94% Accuracy with 1 Year of ScreeningJanuary 20th, 2023
Routine COVID-19 Screening Unnecessary for Cancer OutpatientsFebruary 19th, 2021
PD-L1 as a Biomarker of Response to Immune-Checkpoint InhibitorsFebruary 12th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
